GLG News by Juvederm Users: Cosmetic Dermatologists (US)

This article is important in that it is a good summary of the current knowledge and treatment methods for atopic dermatitis for pediatricians. It is needed in that this condition is inadequately treated, and a periodic refresher is needed for all physicians. Both pharmacologic and non pharmacologic...

This article is important in that it makes the public aware that they should avoid all unlicensed persons who re injecting any substance into their bodies. These especially include those injecting silicone mixtures. The public will become more aware and should have more confidence in licensed practitioners...

The FDA report and scrutiny of LASIK complaints reveals what consientious LASIK surgeons have known for years:  Not everyone who walks through your doors is a good lasik candidate and you should not laser everyone.  About 1 out of 4 patients that consider lasik are actually good candidates...

The light adjustable lens is a lens implant that is placed in the eye like a tradition intraocular lens during cataract surgery.  The unique difference is that it can be treated with a special light after surgical implant (weeks to months later) to correct any residual refractive errors or to fine...

 This article is important in that it lays to rest a misconception that long term repeated use of Botox ( Allergan) leads to decreased efficacy. Efficacy was maintained, and no neutralizing antibodies were found to Botox. This will reassure most users of Botox, and patients as well.

 This article is important in that it defined the incidence of serious skin reactions to the three common TNF antagonists- Enbrel, Humira, and Remicade. The incidence is relatively low in comparison to the numbers of patients treated. Any foreign protein has the potential for eliciting these reactions,...

Anacor's recent release of the data from their phase 2a study of AN 2728  for psoriasis were encouraging.  Over 69% actively treated plaques of psoriasis improved versus only 6% of placebo treated plaques. The study was limited by the short duration- only 28 days versus up to 16...

 This article is important in that it is one of the first to confirm what is  a widely held belief among many dematologists who treat many patients with psoriasis. Specifically that these patients suffer a higher rate of cardiovascular diseases, depression, malignancy, etc. This makes perfect...

Centocors new product- Ustekinumab /CNTO 1275 had impressive results in the recent PHOENIX trials and the application is under review at the FDA. The PASI score reductions are superior to the exiting agents such as Enbrel and Humira, and are comparable to those of the other Centocor product- Remicade...

(Directly pulled from the article.) Patients were randomly assigned to receive 2 doses, 45 or 90 mg, of subcutaneous ustekinumab, given 4 weeks apart and followed by treatments every 12 weeks.  Patients randomly assigned to receive 45 mg had a sustained PASI 75 (indicating an improvement in psoriatic...